Brokerages Expect Petmed Express Inc (PETS) to Announce $0.43 EPS

Wall Street brokerages expect Petmed Express Inc (NASDAQ:PETS) to announce earnings per share of $0.43 for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Petmed Express’ earnings. Petmed Express posted earnings per share of $0.37 in the same quarter last year, which indicates a positive year-over-year growth rate of 16.2%. The business is scheduled to issue its next quarterly earnings report on Monday, May 14th.

According to Zacks, analysts expect that Petmed Express will report full-year earnings of $1.70 per share for the current fiscal year, with EPS estimates ranging from $1.64 to $1.76. For the next financial year, analysts expect that the business will post earnings of $1.94 per share, with EPS estimates ranging from $1.73 to $2.14. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Petmed Express.

Petmed Express (NASDAQ:PETS) last issued its quarterly earnings results on Monday, January 22nd. The company reported $0.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.11. Petmed Express had a net margin of 12.84% and a return on equity of 34.04%. The business had revenue of $60.10 million during the quarter, compared to the consensus estimate of $56.76 million. During the same quarter in the prior year, the firm earned $0.24 EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis.

A number of equities research analysts have issued reports on PETS shares. ValuEngine upgraded shares of Petmed Express from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th. BidaskClub downgraded shares of Petmed Express from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 19th. Northcoast Research set a $58.00 price target on shares of Petmed Express and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Noble Financial restated a “hold” rating on shares of Petmed Express in a research note on Friday, October 27th. Finally, Zacks Investment Research upgraded shares of Petmed Express from a “sell” rating to a “hold” rating and set a $50.00 price target on the stock in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $42.80.

In other news, CEO Menderes Akdag sold 30,000 shares of the stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $51.00, for a total transaction of $1,530,000.00. Following the transaction, the chief executive officer now owns 490,000 shares in the company, valued at approximately $24,990,000. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gian Fulgoni sold 20,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $44.38, for a total transaction of $887,600.00. Following the transaction, the director now owns 55,900 shares in the company, valued at approximately $2,480,842. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,000 shares of company stock worth $3,229,500. 4.00% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of PETS. Schwab Charles Investment Management Inc. grew its stake in Petmed Express by 20.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 84,764 shares of the company’s stock valued at $3,442,000 after buying an additional 14,456 shares during the last quarter. Teachers Advisors LLC grew its stake in Petmed Express by 5.3% in the 2nd quarter. Teachers Advisors LLC now owns 65,173 shares of the company’s stock valued at $2,646,000 after buying an additional 3,289 shares during the last quarter. TIAA CREF Investment Management LLC grew its stake in Petmed Express by 65.0% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 113,930 shares of the company’s stock valued at $4,626,000 after buying an additional 44,889 shares during the last quarter. New York State Common Retirement Fund grew its stake in Petmed Express by 8.2% in the 2nd quarter. New York State Common Retirement Fund now owns 22,400 shares of the company’s stock valued at $909,000 after buying an additional 1,699 shares during the last quarter. Finally, UBS Asset Management Americas Inc. acquired a new position in Petmed Express in the 2nd quarter valued at $280,000. Institutional investors and hedge funds own 96.66% of the company’s stock.

Petmed Express (PETS) traded up $0.37 during mid-day trading on Thursday, reaching $44.06. 384,400 shares of the company’s stock were exchanged, compared to its average volume of 794,982. Petmed Express has a 12 month low of $19.21 and a 12 month high of $57.80. The stock has a market cap of $900.06, a P/E ratio of 26.07, a price-to-earnings-growth ratio of 2.57 and a beta of 0.95.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 16th. Stockholders of record on Monday, February 5th will be paid a dividend of $0.25 per share. This is a positive change from Petmed Express’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend is Friday, February 2nd. This represents a $1.00 annualized dividend and a dividend yield of 2.27%. Petmed Express’s dividend payout ratio is 59.17%.

TRADEMARK VIOLATION WARNING: “Brokerages Expect Petmed Express Inc (PETS) to Announce $0.43 EPS” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/15/brokerages-expect-petmed-express-inc-pets-to-announce-0-43-eps.html.

About Petmed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Get a free copy of the Zacks research report on Petmed Express (PETS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply